A collaboration between Boehringer Ingelheim Canada, community cardiologists and Ensho Health, a health technology company, has created an innovative analytical tool to optimize care for people living with chronic health conditions in Alberta.
The tool uses machine learning algorithms to advance early detection and individualized treatment plans for people living with type 2 diabetes, atherosclerotic cardiovascular disease and heart failure – all aligned with Diabetes Canada’s Clinical Practice Guidelines and the Canadian Cardiovascular Society’s Treatment Guidelines.
Powered by artificial intelligence, the analytical tool also offers the first automated electronic data capture system validated for clinical applications. It provides an analysis that uses machine learning to securely compare data against evidence-based algorithms and guidelines in the search for opportunities that can optimize patient care. Patients can then be recalled for review and collaboration with their healthcare provider to ensure guideline-directed therapies and decisions are being discussed. All analyses are validated for accuracy and have also received Provincial Privacy Impact Assessment approval.
Work is ongoing to expand the program by helping participating specialists to identify patients under their care.
This collaboration is an example of how delivering innovative, digital solutions to patients can help improve health outcomes, and bring sustainable and transformative change to improve the healthcare system. For more information, please contact the project lead.